New shot aims to slash hepatitis b virus levels

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing and able to give written informed consent for study participation; 2. Male or female participants aged 18-65 years; 3. Body mass index (BMI) within the range of 18-34 kilograms/square meter (kg/m2); 4. Documented history of chronic hepatitis B virus (HBV) infection, by positive HBsAg and/or HBV DNA tests ≥ 6 months before screening; 5. HBeAg positive or negative at screening; 6. On a stable regimen (≥ 12 months before screening) of any approved first-line oral NAs; 7. HBV DNA level \<100 IU/mL at screening; 8. HBsAg level ≥50 IU/mL at screening; 9. Serum alanine aminotransferase (ALT) ≤ 1.5 times the upper limit of normal (ULN); 10. Liver transient elastography (FibroScan) results within 12 months before screening or at screening showing that the liver stiffness measurement (LSM) level is less than 9 kPa; or with liver biopsy within 24 months before screening showing that the Metavir score is F0-F2; Exclusion Criteria: 1. Diagnosed with other liver diseases other than hepatitis B; 2. History of liver cirrhosis or hepatic decompensation (e.g., ascites, varices bleeding, or hepatic encephalopathy) before or at screening; 3. History of organ transplantation or previous or concurrent with hepatocellular carcinoma (HCC), or imaging findings suggesting a possibility of malignant liver lesions; 4. Concurrent hepatitis C virus (HCV), human immunodeficiency virus (HIV), or diagnosis of syphilis, acute hepatitis A or acute hepatitis E; 5. Laboratory results at screening as follows: serum alpha-fetoprotein (AFP) \>50 μg/L; serum albumin concentration \<3.0 g/dL; international normalized ratio (INR) \>1.5; platelet count \<90×10\^9/L; serum direct bilirubin (DB) \>2×ULN; serum creatinine concentration \>1.5×ULN or creatinine clearance \<60 mL/min (according to the Cockcroft-Gault equation); or any clinically significant laboratory outliers that the investigator believes may interfere with the interpretation of the efficacy and safety data in this study; 6. Those who the investigator believes are not suitable to participate in the study due to other factors.